JAK2 and Alzheimer disease: In the future, other inhibitors or genetic knockdown of JAK2/STAT3 in VSMCs are important to explore its role in CCDC80 regulation of AD, and clinical research must confirm if WP1066 can be used in a therapy to delay the progression of AD.